

```

chain nodes :
  18  21
ring nodes :
  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17
chain bonds :
  2-18  5-8  7-14  11-21
ring bonds :
  1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-11  8-9  9-10  10-11  12-13  12-17  13-14  14-15  15-16
  16-17
exact/norm bonds :
  1-2  1-6  2-3  2-18  3-4  4-5  5-6  7-8  7-11  7-14  8-9  9-10  10-11
exact bonds :
  5-8  11-21
normalized bonds :
  12-13  12-17  13-14  14-15  15-16  16-17
isolated ring systems :
  containing 1 : 7 : 12 :

```

```

Match level :
  1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom  11:Atom
  12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 21:CLASS
Generic attributes :
  18:
  Saturation      : Unsaturated
  Number of Carbon Atoms : less than 7
  Type of Ring System   : Monocyclic

```


```

Element Count :
  Node 18: Limited
    C,C4-5
    N,N1-2
    O,O0
    S,S0

```

=&gt;

Uploading C:\Program Files\Stnexp\Queries\10588876.str



chain nodes :

18 21

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

chain bonds :

2-18 5-8 7-14 11-21

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11 12-13 12-17 13-14

14-15 15-16 16-17

exact/norm bonds :

1-2 1-6 2-3 2-18 3-4 4-5 5-6 7-8 7-11 7-14 8-9 9-10 10-11

exact bonds :

5-8 11-21

normalized bonds :

12-13 12-17 13-14 14-15 15-16 16-17

isolated ring systems :

containing 1 : 7 : 12 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 21:CLASS

Generic attributes :

18:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

Element Count :

Node 18: Limited

C,C4-5

N,N1-2

O,O0

S,S0


10/588,876

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 14:56:25 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 101 TO ITERATE

100.0% PROCESSED 101 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 1418 TO 2622

PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> => s l1 sss ful

FULL SEARCH INITIATED 14:56:59 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1737 TO ITERATE

100.0% PROCESSED 1737 ITERATIONS

21 ANSWERS

SEARCH TIME: 00.00.01

L3 21 SEA SSS FUL L1

=> => s l3

L4 2 L3

=> d l4 1-2 bib,ab,hitstr

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:962050 CAPLUS  
 DN 143:266931  
 TI Preparation of triazoles which inhibit vasopressin antagonistic activity  
 IN Bryans, Justin Stephen; Johnson, Patrick Stephen; Ryckmans, Thomas;  
 Stobie, Alan  
 PA Pfizer Limited, UK; Pfizer Inc.  
 SO PCT Int. Appl., 55 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

Applicant's

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005079808	A1	20050901	WO 2005-IB79	20050111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2554090	A1	20050901	CA 2005-2554090	20050111
EP 1708718	A1	20061011	EP 2005-702246	20050111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
BR 2005006994	A	20070703	BR 2005-6994	20050111
JP 2007518788	T	20070712	JP 2006-550326	20050111
MX 2006PA08355	A	20061106	MX 2006-PA8355	20060721
US 2007203132	A1	20070830		20070129
PRAI GB 2004-1384	A	20040122		
US 2004-549407P	P	20040301		
WO 2005-IB79	W	20050111		
WO 2005-IB9	W	20050111		
OS MARPAT 143:266931				
AB The title compds. I [Het = 2-pyridinyl or 2-pyrimidinyl; R1 = H, alkyl or a nitrogen-containing heterocyclic ring having 5-6 ring atoms; R2 = H, benzyl or alkyl; and R3 = H, Me, OMe or Cl], useful for treating anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittelsmerchz, preclampsia, premature ejaculation, premature (preterm) labor and Raynaud's disease, were prepared Thus, heating 2-[4-(5-methyl-[1,3,4]oxadiazol-2-yl)piperidin-1-yl]pyrimidine (preparation given) with 2-ethylphenylamine in the presence of MgCl2 in a sealed vessel at 150°C for 18 h afforded I [Het = 2-pyrimidinyl; R1 = H; R2 = Et; R3 = H]. All the exemplified compds. I showed a Ki of less than 400 nM when tested in screen 1.0 (V1A filter binding assay).				
IT 863780-52-3P 863780-53-4P 863780-54-5P 863780-55-6P 863780-56-7P 863780-57-8P 863780-58-9P 863780-59-0P 863780-60-3P 863780-61-4P 863780-62-5P 863780-63-6P				


863780-64-7P 863780-65-8P 863780-66-9P  
 863780-68-1P 863780-69-2P 863780-71-6P  
 863780-72-7P 863780-73-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of triazoles which inhibit vasopressin antagonistic activity)


RN 863780-52-3 CAPLUS

CN Pyrimidine, 2-[4-[4-(2-ethylphenyl)-5-methyl-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (CA INDEX NAME)




RN 863780-53-4 CAPLUS

CN Pyrimidine, 2-[4-[5-methyl-4-(2-propylphenyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (CA INDEX NAME)




RN 863780-54-5 CAPLUS

CN Pyrimidine, 2-[4-[5-methyl-4-[2-(1-methylethyl)phenyl]-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (CA INDEX NAME)




RN 863780-55-6 CAPLUS

CN Morpholine, 4-[[4-phenyl-5-[1-(2-pyrimidinyl)-4-piperidinyl]-4H-1,2,4-triazol-3-yl]methyl]- (CA INDEX NAME)




RN 863780-56-7 CAPLUS

CN Pyrimidine, 2-[4-(5-butyl-4-phenyl-4H-1,2,4-triazol-3-yl)-1-piperidinyl]- (CA INDEX NAME)




RN 863780-57-8 CAPLUS

CN Pyrimidine, 2-[4-[4-phenyl-5-(1-piperidinylmethyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (CA INDEX NAME)



RN 863780-58-9 CAPLUS


CN Pyrimidine, 2-[4-(5-methyl-4-phenyl-4H-1,2,4-triazol-3-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 863780-59-0 CAPLUS


CN Pyridine, 2-[4-[4-(4-methoxy-2-methylphenyl)-5-methyl-4H-1,2,4-triazol-3-

yl]-1-piperidinyl]- (CA INDEX NAME)




RN 863780-60-3 CAPLUS

CN Pyridine, 2-[4-[4-(4-chloro-2-methylphenyl)-5-methyl-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (CA INDEX NAME)




RN 863780-61-4 CAPLUS

CN Pyridine, 2-[4-[5-methyl-4-(2-methylphenyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (CA INDEX NAME)




RN 863780-62-5 CAPLUS

CN Pyridine, 2-[4-[4-(4-chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (CA INDEX NAME)




RN 863780-63-6 CAPLUS

CN Pyridine, 2-[4-[4-(4-methoxyphenyl)-5-(2H-1,2,3-triazol-2-ylmethyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (CA INDEX NAME)



RN 863780-64-7 CAPLUS


CN Pyridine, 2-[4-[4-(4-methoxyphenyl)-5-methyl-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (CA INDEX NAME)



RN 863780-65-8 CAPLUS


CN Pyridine, 2-[4-[4-(2-methylphenyl)-5-(2H-1,2,3-triazol-2-ylmethyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (CA INDEX NAME)






RN 863780-66-9 CAPLUS

CN Pyridine, 2-[4-[4-(4-chloro-2-methylphenyl)-5-(2H-1,2,3-triazol-2-ylmethyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (CA INDEX NAME)




RN 863780-68-1 CAPLUS

CN Pyridine, 2-[4-[4-phenyl-5-(2H-1,2,3-triazol-2-ylmethyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (CA INDEX NAME)




RN 863780-69-2 CAPLUS

CN Pyridine, 2-[4-[4-(4-chlorophenyl)-5-(2H-1,2,3-triazol-2-ylmethyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (CA INDEX NAME)




RN 863780-71-6 CAPLUS

CN Pyridine, 2-[4-[5-methyl-4-(4-methylphenyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (CA INDEX NAME)




RN 863780-72-7 CAPLUS

CN Pyridine, 2-[4-[4-(2,4-dimethylphenyl)-5-methyl-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (CA INDEX NAME)



RN 863780-73-8 CAPLUS

CN Morpholine, 4-[4-(4-chloro-2-methylphenyl)-5-[1-(2-pyridinyl)-4-piperidinyl]-4H-1,2,4-triazol-3-yl]methyl]- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2004:718543 CAPLUS  
 DN 141:225517  
 TI Preparation of triazoles as vasopressin receptor V1a antagonists for  
 treating of dysmenorrhea  
 IN Bryans, Justin Stephen; Johnson, Patrick Stephen; Ryckmans, Thomas;  
 Stobie, Alan  
 PA Pfizer Limited, UK; Pfizer Inc.  
 SO PCT Int. Appl., 164 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

common inventors

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004074291	A1	20040902	WO 2004-IB432	20040209
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004213242	A1	20040902	AU 2004-213242	20040209
	AU 2004213242	B2	20070419		
	CA 2516557	A1	20040902	CA 2004-2516557	20040209
	EP 1597260	A1	20051123	EP 2004-709303	20040209
	EP 1597260	B1	20061227		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2004007676	A	20060301	BR 2004-7676	20040209
	CN 1751047	A	20060322	CN 2004-80004708	20040209
	JP 2006517921	T	20060803	JP 2006-500323	20040209
	AT 349449	T	20070115	AT 2004-709303	20040209
	ES 2277237	T3	20070701	ES 2004-4709303	20040209
	US 2004186091	A1	20040923	US 2004-782285	20040218
	US 7119088	B2	20061010		
	NL 1025527	A1	20040823	NL 2004-1025527	20040219
	NL 1025527	C2	20050314		
	AT 380048	T	20071215	AT 2004-743961	20040712
	US 2005026810	A1	20050203	US 2004-895630	20040720
	IN 2005DN03308	A	20070713	IN 2005-DN3308	20050726
	MX 2005PA08923	A	20060309	MX 2005-PA8923	20050819
	KR 750028	B1	20070816	KR 2005-715408	20050819
	NO 2005004053	A	20051031	NO 2005-4053	20050831
	US 2006194794	A1	20060831	US 2006-416498	20060501
	JP 2007045838	A	20070222	JP 2006-277701	20061011
PRAI	GB 2003-3852	A	20030219		
	GB 2003-17227	A	20030723		
	US 2003-455455P	P	20030318		
	US 2003-493823P	P	20030808		
	JP 2006-500323	A3	20040209		
	WO 2004-IB432	W	20040209		
	US 2004-782285	A3	20040218		
OS	MARPAT 141:225517				
AB	Title compds. I [wherein V = -(CH <sub>2</sub> )d(O)e-, -CO-, -CH(alkyl)-; W = O,				

S(:O)a, NH and derivs.; X, Y = independently H, alkyl, halo, OH, CF<sub>3</sub>, OCF<sub>3</sub>, alkoxy, Z = -(CH<sub>2</sub>)<sub>f</sub>(O)g-, -CO-, -CH(alkyl)-; A = 4-7 membered (un)substituted saturated N-containing heterocycle; B = Ph, (un)substituted saturated N-containing heterocycle; a = 0-2; e, g = 0-1; d, f = 1-2; and their pharmaceutically acceptable derivs.] were prepared as vasopressin receptor V1a antagonists for the treatment of dysmenorrhea. Thus, amination of chloride II (preparation given) with 2-aminomethyl-4-chlorophenylamine (preparation given), cyclization of the aminooxadiazole, and reaction of amine with dimethylsulphamoyl chloride gave the triazole III. III displayed a K<sub>i</sub> = 0.24 nM in a V1a filter binding assay.


IT 748806-15-7P, [4-Chloro-2-[1-[[[4-(4-chlorophenyl)-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H-[1,2,4]triazol-3-yl]methyl]methylamino]ethyl]phenyl]amine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

RN 748806-15-7 CAPLUS

CN 4H-1,2,4-Triazole-3-methanamine, N-[1-(2-amino-5-chlorophenyl)ethyl]-4-(4-chlorophenyl)-N-methyl-5-[1-(2-pyrimidinyl)-4-piperidinyl]- (CA INDEX NAME)



RE.CNT 9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/588,876

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

11.38

190.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-1.60

-1.60

STN INTERNATIONAL LOGOFF AT 14:57:30 ON 07 JAN 2008